X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7687) 7687
neutropenia - chemically induced (6893) 6893
female (5402) 5402
male (4771) 4771
middle aged (4414) 4414
adult (4058) 4058
aged (3755) 3755
oncology (3212) 3212
antineoplastic combined chemotherapy protocols - adverse effects (2337) 2337
antineoplastic combined chemotherapy protocols - therapeutic use (2231) 2231
chemotherapy (2003) 2003
neutropenia (1911) 1911
treatment outcome (1875) 1875
antineoplastic agents - adverse effects (1635) 1635
cancer (1340) 1340
drug administration schedule (1307) 1307
thrombocytopenia - chemically induced (1180) 1180
neoplasms - drug therapy (1080) 1080
adolescent (1038) 1038
pharmacology & pharmacy (1036) 1036
hematology (999) 999
aged, 80 and over (992) 992
granulocyte colony-stimulating factor - therapeutic use (839) 839
dose-response relationship, drug (834) 834
retrospective studies (801) 801
therapy (786) 786
neutropenia - drug therapy (770) 770
antineoplastic combined chemotherapy protocols - administration & dosage (715) 715
child (690) 690
lung neoplasms - drug therapy (690) 690
breast neoplasms - drug therapy (672) 672
risk factors (669) 669
antineoplastic agents - therapeutic use (666) 666
neutropenia - complications (645) 645
neutropenia - prevention & control (629) 629
colony-stimulating factor (618) 618
disease-free survival (616) 616
trial (599) 599
infusions, intravenous (598) 598
medicine & public health (591) 591
animals (581) 581
cisplatin (577) 577
cisplatin - administration & dosage (567) 567
survival analysis (560) 560
agranulocytosis - chemically induced (556) 556
paclitaxel - administration & dosage (554) 554
care and treatment (543) 543
remission induction (526) 526
prospective studies (514) 514
anemia - chemically induced (513) 513
survival rate (499) 499
child, preschool (496) 496
antineoplastic agents - administration & dosage (482) 482
febrile neutropenia (480) 480
leukopenia - chemically induced (477) 477
toxicity (467) 467
cyclophosphamide - administration & dosage (466) 466
filgrastim (447) 447
neoplasm staging (442) 442
time factors (441) 441
paclitaxel (425) 425
leukocyte count (424) 424
carcinoma, non-small-cell lung - drug therapy (423) 423
follow-up studies (423) 423
medicine, general & internal (420) 420
paclitaxel - adverse effects (419) 419
young adult (417) 417
drug therapy (416) 416
doxorubicin - administration & dosage (415) 415
deoxycytidine - analogs & derivatives (412) 412
docetaxel (402) 402
granulocyte colony-stimulating factor - administration & dosage (397) 397
fever - chemically induced (393) 393
nausea - chemically induced (391) 391
recombinant proteins (391) 391
drug therapy, combination (386) 386
research (385) 385
fluorouracil - administration & dosage (383) 383
diarrhea - chemically induced (379) 379
cyclophosphamide (378) 378
camptothecin - analogs & derivatives (367) 367
survival (361) 361
deoxycytidine - administration & dosage (353) 353
combination (348) 348
combined modality therapy (346) 346
analysis (342) 342
prognosis (340) 340
pharmacokinetics (339) 339
carboplatin - administration & dosage (337) 337
cyclophosphamide - adverse effects (336) 336
fever (331) 331
antineoplastic agents, phytogenic - adverse effects (326) 326
infant (323) 323
taxoids - administration & dosage (323) 323
cisplatin - adverse effects (320) 320
anti-bacterial agents - therapeutic use (319) 319
doxorubicin (315) 315
pediatrics (315) 315
etoposide - administration & dosage (313) 313
breast cancer (312) 312
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7442) 7442
Japanese (217) 217
French (152) 152
Spanish (106) 106
Chinese (103) 103
German (74) 74
Russian (26) 26
Polish (23) 23
Italian (22) 22
Hungarian (18) 18
Czech (6) 6
Danish (6) 6
Dutch (6) 6
Finnish (5) 5
Portuguese (5) 5
Swedish (3) 3
Hebrew (2) 2
Bulgarian (1) 1
Croatian (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 770 - 778
Summary Background Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MITOCHONDRIAL METABOLISM | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Sulfides - administration & dosage | Pancreatic Neoplasms - drug therapy | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Hyperglycemia - chemically induced | Leucovorin - adverse effects | Fluorouracil - adverse effects | Hypokalemia - chemically induced | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Hematologic Diseases - chemically induced | Sensation Disorders - chemically induced | Abdominal Pain - chemically induced | Pancreatic Neoplasms - pathology | Anemia - chemically induced | Thrombocytopenia - chemically induced | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Hypoalbuminemia - chemically induced | Maximum Tolerated Dose | Sepsis - chemically induced | Sulfides - adverse effects | Aged | Caprylates - administration & dosage | Caprylates - adverse effects | Organoplatinum Compounds - adverse effects | Lymphopenia - chemically induced | Enzymes | Medical colleges | Care and treatment | Metastasis | Antineoplastic agents | Cells | Antimitotic agents | Cancer patients | Chemotherapy | Pancreatic cancer | Physiological aspects | Product development | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 946 - 957
Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in... 
Hematology, Oncology and Palliative Medicine | Dacarbazine - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | N-Myc Proto-Oncogene Protein - genetics | Neoplasm Recurrence, Local - drug therapy | Infant | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Pain - chemically induced | Fever - chemically induced | Infection - chemically induced | Ganglioneuroblastoma - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Hypokalemia - chemically induced | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Ganglioneuroblastoma - drug therapy | Neutropenia - chemically induced | Child | Sirolimus - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Dacarbazine - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Sirolimus - analogs & derivatives | Ganglioneuroblastoma - genetics | Neuroblastoma - genetics | Anemia - chemically induced | Neuroblastoma - diagnostic imaging | Survival Rate | Thrombocytopenia - chemically induced | Disease-Free Survival | Retreatment | Sirolimus - administration & dosage | Gene Amplification | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Neoplasm Recurrence, Local - genetics | Hypoxia - chemically induced | Medical colleges | Stem cells | Neuroblastoma
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 200 - 211
Journal Article
Blood, ISSN 1528-0020, 2015, Volume 126, Issue 6, pp. 739 - 745
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 83 - 98.e4
Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque... 
Dermatology | pooled analysis | phase II studies | phase III studies | psoriasis | secukinumab | long-term safety | Phase III studies | Secukinumab | Long-term safety | Pooled analysis | Psoriasis | Phase II studies | CONTROLLED-TRIAL | CONFIDENCE-INTERVALS | FOLLOW-UP | RISK | long | DERMATOLOGY | LONGITUDINAL ASSESSMENT | CANDIDA-ALBICANS | REGISTRY PSOLAR | DISEASE | DOUBLE-BLIND | HOST-DEFENSE | term safety | Severity of Illness Index | Etanercept - adverse effects | Psoriasis - drug therapy | Etanercept - administration & dosage | Mental Disorders - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Infection - chemically induced | Randomized Controlled Trials as Topic | Clinical Trials, Phase III as Topic | Neoplasms - chemically induced | Interleukin-17 - antagonists & inhibitors | Time Factors | Antibodies, Monoclonal - administration & dosage | Adult | Female | Immunosuppressive Agents - adverse effects | Inflammatory Bowel Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Neutropenia - chemically induced | Immunosuppressive Agents - administration & dosage | Clinical Trials, Phase II as Topic | Medical research | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Pharmaceutical industry | Consulting services
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2017, Volume 117, Issue 7, pp. 938 - 946
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article
Journal Article